about
A framework for community ownership of a text messaging programme to improve adherence to antiretroviral therapy and client-provider communication: a mixed methods study.Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.Cryptococcal meningitis: A neglected NTD?Adherence as a predictor of sexual behaviors in people living with HIV/AIDS during the first year of antiretroviral therapy in rural Cameroon: data from Stratall ANRS 12110/ESTHER trialDeterminants of retention in care in an antiretroviral therapy (ART) program in urban Cameroon, 2003-2005.Barriers to the implementation of mobile phone reminders in pediatric HIV care: a pre-trial analysis of the Cameroonian MORE CARE study.The Cameroon Mobile Phone SMS (CAMPS) trial: a randomized trial of text messaging versus usual care for adherence to antiretroviral therapy.Impact of HIV comprehensive care and treatment on serostatus disclosure among Cameroonian patients in rural district hospitals.Changes in sexual activity and risk behaviors among PLWHA initiating ART in rural district hospitals in Cameroon -- data from the STRATALL ANRS 12110/ESTHER trial.Susceptibility to transmitting HIV in patients initiating antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER Trial)Factors associated with non-adherence to scheduled medical follow-up appointments among Cameroonian children requiring HIV care: a case-control analysis of the usual-care group in the MORE CARE trial.Investigation of minor species Candida africana, Candida stellatoidea and Candida dubliniensis in the Candida albicans complex among Yaoundé (Cameroon) HIV-infected patients.Antiretroviral drug resistance and routine therapy, Cameroon.Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in AfricaAdherence to Antiretroviral Therapy (ART) in Yaoundé-Cameroon: Association with Opportunistic Infections, Depression, ART Regimen and Side Effects.Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in CameroonMolecular and Genetic Characterization of HIV-1 Tat Exon-1 Gene from Cameroon Shows Conserved Tat HLA-Binding Epitopes: Functional Implications.Increased burden and severity of metabolic syndrome and arterial stiffness in treatment-naïve HIV+ patients from Cameroon.A randomized blinded controlled trial of mobile phone reminders on the follow-up medical care of HIV-exposed and HIV-infected children in Cameroon: study protocol (MORE CARE)Virologic Failure and Human Immunodeficiency Virus Drug Resistance in Rural Cameroon With Regard to the UNAIDS 90-90-90 Treatment Targets.Time patterns of adherence and long-term virological response to non-nucleoside reverse transcriptase inhibitor regimens in the Stratall ANRS 12110/ESTHER trial in Cameroon.Gender Differences in Adherence and Response to Antiretroviral Treatment in the Stratall Trial in Rural District Hospitals in Cameroon.Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon.Bio-monitoring of mycotoxin exposure in Cameroon using a urinary multi-biomarker approach.Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients.Genetic diversity of the Hwp1 gene and HIS3, EF3, CDC3 microsatellites and antifungal susceptibility profiles of Candida albicans isolates from Yaoundé HIV-infected patients.Cryptococcus neoformans isolates from Yaoundé human immunodeficiency virus-infected patients exhibited intra-individual genetic diversity and variation in antifungal susceptibility profiles between isolates from the same patient.Short Communication: Population-Based Surveillance of HIV-1 Drug Resistance in Cameroonian Adults Initiating Antiretroviral Therapy According to the World Health Organization Guidelines.Benefits of task-shifting HIV care to nurses in terms of health-related quality of life in patients initiating antiretroviral therapy in rural district hospitals in Cameroon [Stratall Agence Nationale de Recherche sur le SIDA (ANRS) 12110/Ensemble pCryptoccocal meningitis in Yaoundé (Cameroon) HIV infected patients: Diagnosis, frequency and Cryptococcus neoformans isolates susceptibility study to fluconazole.Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon.Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy.Task shifting HIV care in rural district hospitals in Cameroon: evidence of comparable antiretroviral treatment-related outcomes between nurses and physicians in the Stratall ANRS/ESTHER trial.Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine.Effects of antiretroviral therapy on arterial stiffness in Cameroonian HIV-infected patients.Successful integrase inhibitor-based highly active antiretroviral therapy for a multidrug-class-resistant HIV type 1 group O-infected patient in Cameroon.Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaoundé, Cameroon.Prediction of HIV drug resistance based on virologic, immunologic, clinical, and/or adherence criteria in the Stratall ANRS 12110/ESTHER trial in Cameroon.
P50
Q30607367-E941B692-492F-41C4-9BBC-4AA4FEFE4237Q33535469-80F8A78E-7D81-4704-A4AF-AFF4E19E9870Q33852819-16C11EFE-6168-45AB-9DA1-56D65CD8FB9EQ34305106-F2DFCC55-C6DD-43DF-A1FE-A3C56A700458Q34320918-2E45F5C9-8564-4442-BB6A-41B587B13299Q34451837-D28121B0-7E11-4DC5-9366-684B7825683FQ34510224-3D3925B4-9C46-4E51-80ED-B6F04469DFC5Q34576235-83444A49-D5BB-4077-A117-AC114404CF56Q34643223-29778B92-D171-4024-BAC4-73365D57FC03Q34701860-25A0DEB1-3EAE-4C00-81D5-692BD1B2083BQ35065997-718391A6-18B7-4304-B60D-1AD42A8DCDCEQ35307936-603476E9-F6B5-4C34-9C77-B8B74C3946ACQ35817460-D362B1EE-5CE9-4F03-B774-A17F11118835Q35853812-48D7BD2F-C67B-4F0B-A55E-6E2A37E1821BQ36265139-5ED5BD03-53C3-4661-A1EF-32F6012522E2Q36581795-98642684-208B-4D2E-ADC3-F6A0481B75F7Q37153763-6CD345A2-B80E-48E0-B471-8102BA7EA469Q37169956-0970CE38-587D-4E2A-BE9C-DA47E3AD8A5FQ37361370-827ABBE2-D08A-4C33-8995-1A9861929181Q37517997-BE457387-DC7B-4443-A6E3-DB85ED58ADE9Q38410798-8467DDA1-1E24-4390-B886-1BDFEFA03296Q38917366-913E2907-CB9F-4447-BA1F-A9A44B083E92Q39146597-76CA7B7D-6F39-49CC-8C59-3F03992D2CBDQ39332200-1A68DC2F-782F-4B4B-9446-158C3BBA613EQ39995698-CCE36D65-D2EC-43BE-B61C-8A715DA2E6A7Q40505796-5AEF63E2-0489-48A7-87AE-93A5B4DA0C28Q40705232-8E77D6E0-D9B0-4F60-88ED-55F9A1623FEDQ40896891-B3A9BCFF-84EF-4305-BAE6-B04FA227E243Q41345191-3EBE544E-49B4-4632-A446-61E05B8D3500Q41622633-2B3CEE3A-05A6-43C5-98A4-17290D56CD23Q42234067-89790B83-8F56-4BA2-9CAC-DBC576F84A35Q42630740-B88A3F8F-CB33-4D28-9F57-2F87A3BEEE9EQ42839642-30A82E54-2561-4E0C-BD1A-5E36BBF9D514Q42989987-4CB36CC0-7268-41F9-A97A-AC967BD705F7Q44248458-AAB5EA81-838D-4A7C-8ABD-66721D860DCBQ44332716-49A2F958-E40F-4976-AC83-D7A49B20C850Q44427927-6CEBA7C4-0B95-43AE-AA3A-74E25EBCC7C6Q44600312-ECFEE7CF-2C1A-456E-A5B7-B4BEC302AA25Q44644328-621EB24C-E4A8-4761-AEC4-3C87DB5A4EABQ44666478-6F9A6C65-3A6B-478C-9222-2956088510AB
P50
name
Charles Kouanfack
@ast
Charles Kouanfack
@da
Charles Kouanfack
@de
Charles Kouanfack
@en
Charles Kouanfack
@es
Charles Kouanfack
@nl
type
label
Charles Kouanfack
@ast
Charles Kouanfack
@da
Charles Kouanfack
@de
Charles Kouanfack
@en
Charles Kouanfack
@es
Charles Kouanfack
@nl
prefLabel
Charles Kouanfack
@ast
Charles Kouanfack
@da
Charles Kouanfack
@de
Charles Kouanfack
@en
Charles Kouanfack
@es
Charles Kouanfack
@nl